Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARA 290 in Diabetic Macular Oedema
NCT06626971Phase 2Terminated
- Sponsor
- Belfast Health and Social Care Trust
- Start
- Apr 2016
- Primary completion
- May 2017
- Modality
- Recombinant Proteins and Enzymes, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of cibinetide in diabetic macular edema (DME), sponsored by Belfast Health and Social Care Trust. Primary endpoint: Best Corrected Visual Acuity at 12 weeks. Started Apr 2016; status: terminated.
02
Drugs
cibinetide
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT06626971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06626971.